BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huisman TM, Dieterich DT, Friedman SL. Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update. J Exp Pharmacol 2021;13:329-38. [PMID: 33776490 DOI: 10.2147/JEP.S265286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Salvati A, Poelstra K. Drug Targeting and Nanomedicine: Lessons Learned from Liver Targeting and Opportunities for Drug Innovation. Pharmaceutics 2022;14:217. [DOI: 10.3390/pharmaceutics14010217] [Reference Citation Analysis]
2 Foglia B, Novo E, Protopapa F, Maggiora M, Bocca C, Cannito S, Parola M. Hypoxia, Hypoxia-Inducible Factors and Liver Fibrosis. Cells 2021;10:1764. [PMID: 34359934 DOI: 10.3390/cells10071764] [Reference Citation Analysis]
3 De Smet V, Eysackers N, Merens V, Kazemzadeh Dastjerd M, Halder G, Verhulst S, Mannaerts I, van Grunsven LA. Initiation of hepatic stellate cell activation extends into chronic liver disease. Cell Death Dis 2021;12:1110. [PMID: 34839349 DOI: 10.1038/s41419-021-04377-1] [Reference Citation Analysis]
4 Rajak S, Gupta P, Anjum B, Raza S, Tewari A, Ghosh S, Tripathi M, Singh BK, Sinha RA. Role of AKR1B10 and AKR1B8 in the pathogenesis of non-alcoholic steatohepatitis (NASH) in mouse. Biochim Biophys Acta Mol Basis Dis 2021;:166319. [PMID: 34954342 DOI: 10.1016/j.bbadis.2021.166319] [Reference Citation Analysis]
5 Kawashita E, Ozaki T, Ishihara K, Kashiwada C, Akiba S. Endothelial group IVA phospholipase A2 promotes hepatic fibrosis with sinusoidal capillarization in the early stage of a non-alcoholic steatohepatitis in mice. Life Sciences 2022. [DOI: 10.1016/j.lfs.2022.120355] [Reference Citation Analysis]